Main Article Content
ASTHMA, INTERLEUKIN-9, POLYMORPHISM
Background: Asthma is a chronic inflammatory disease of airways which accounts for a huge economic, morbidity and mortality burden. There are different cytokines that contribute to asthma pathophysiology. Learning about these cytokines leads to attaining novel anti-inflammatory treatments for asthma control.
Objectives: The objective of this study is to investigate the association between interleukin-9 serum level and gene polymorphism with asthma susceptibility.
Methods: This was a case-control study of 70 asthmatic patients and 77 healthy control adults aged 18-60. Asthma diagnosis and severity were based on physician diagnosis, pulmonary function test (PFT) and 2016 guild line of Global Initiative for Asthma (GINA). Interleukin 9(IL -9) serum level was measured using sandwich enzyme linked immunosorbent assay. IL9 promoter single nucleotide polymorphism (SNP) (rs2069882) was also assessed using Real-Time PCR System.
Results: There was no significant association between IL-9 SNP polymorphism and asthma. IL-9 serum level was significantly associated with asthma susceptibility (p value= 0.016) and absolute eosinophil count (AEC) (P value=0.033) however its corelation with atopic asthma type, asthma sivierity and Immunoglubin E serum level were not statistically significant.
Conclusion: Although there was no association between IL-9 SNP and asthma, but IL-9 serum level was significantly correlated with asthma susceptibility and AEC.
2. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol, 1991. 88(3 Pt 2): p. 425-534.
3. To, T., et al., Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 2012. 12: p. 204.
4. Prevention USCfDCa. National Surveillance of Asthma: United States, 2001–2010. Available from: http://www.cdc.gov/nchs/data/series/sr_03/sr03_035.pdf.
5. Wechsler, M.E., Getting control of uncontrolled asthma. Am J Med, 2014. 127(11): p. 1049-59.
6. Khorasanizadeh, M., et al., Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Ralpha, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol, 2016. 35(4): p. 294-311.
7. Khorasanizadeh, M., et al., Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther, 2017.
8. Loftus, P.A. and S.K. Wise, Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol, 2015. 5 Suppl 1: p. S7-10.
9. Hambly, N. and P. Nair, Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med, 2014. 20(1): p. 87-94.
10. Yssel, H. and H. Groux, Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol, 2000. 121(1): p. 10-8.
11. Soussi-Gounni, A., M. Kontolemos, and Q. Hamid, Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol, 2001. 107(4): p. 575-82.
12. Zhou, Y., M. McLane, and R.C. Levitt, Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res, 2001. 2(2): p. 80-4.
13. Xing, J., Y. Wu, and B. Ni, Th9: a new player in asthma pathogenesis? J Asthma, 2011. 48(2): p. 115-25.
14. Farahani, R., et al., Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res, 2014. 3: p. 127.
15. Global Initiative for Asthma (GINA). 2012 revision. [April 13, 2017]]; Available from: www.ginasthma.com.
16. Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319-38.
17. Antunes, J., et al., Skin prick tests and allergy diagnosis. Allergol Immunopathol (Madr), 2009. 37(3): p. 155-64.
18. Waldman, I.D. and B.F. Robinson, Meta-analysis of sib pair linkage studies of asthma and the interleukin-9 gene (IL9). Genet Epidemiol, 2001. 21 Suppl 1: p. S109-14.
19. Wang, T.N., et al., The synergistic effects of the IL-9 gene and environmental exposures on asthmatic Taiwanese families as determined by the transmission/disequilibrium test. Int J Immunogenet, 2006. 33(2): p. 105-10.
20. Marsh, D.G., et al., Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science, 1994. 264(5162): p. 1152-6.
21. Noguchi, E., et al., Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med, 1997. 156(5): p. 1390-3.
22. Laitinen, T., et al., Genetic control of serum IgE levels and asthma: linkage and linkage disequilibrium studies in an isolated population. Hum Mol Genet, 1997. 6(12): p. 2069-76.
23. Hizawa, N., et al., Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). J Allergy Clin Immunol, 1998. 102(3): p. 449-53.
24. Louahed, J., et al., IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones. J Immunol, 1995. 154(10): p. 5061-70.
25. Dugas, B., et al., Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol, 1993. 23(7): p. 1687-92.
26. Kearley, J., et al., IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med, 2011. 183(7): p. 865-75.
27. Raeiszadeh Jahromi, S., et al., IL-10 and IL-17F Promoter Single Nucleotide Polymorphism and Asthma: A Case-Control Study in South India. Lung, 2015. 193(5): p. 739-47.
28. Desai, D. and C. Brightling, Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol, 2009. 158(1): p. 10-9.
29. Finiasz, M., et al., The role of cytokines in atopic asthma. Curr Med Chem, 2011. 18(10): p. 1476-87.
30. Desai, D. and C. Brightling, Cytokines and cytokine-specific therapy in asthma. Adv Clin Chem, 2012. 57: p. 57-97.